These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30016989)

  • 41. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
    Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
    Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors.
    Clouse ME; Perry L; Stuart K; Stokes KR
    Digestion; 1994; 55 Suppl 3():92-7. PubMed ID: 7698544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Image-Guided Transarterial Chemoembolization With Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) for Unresectable Hepatic Metastases from Melanoma: Technique and Outcomes.
    Rostas J; Tam A; Sato T; Kelly L; Tatum C; Scoggins C; McMasters K; Martin RCG
    Cardiovasc Intervent Radiol; 2017 Sep; 40(9):1392-1400. PubMed ID: 28508253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis.
    Ni JY; Xu LF; Wang WD; Sun HL; Chen YT
    World J Gastroenterol; 2014 Dec; 20(45):17206-17. PubMed ID: 25493037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases?
    Hung JS; Chang MC; Lee PH; Tien YW
    World J Surg; 2007 Dec; 31(12):2392-7. PubMed ID: 17960455
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.
    Fiore F; Del Prete M; Franco R; Marotta V; Ramundo V; Marciello F; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A
    Endocrine; 2014 Sep; 47(1):177-82. PubMed ID: 24385266
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
    Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
    AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
    Richardson AJ; Laurence JM; Lam VW
    J Vasc Interv Radiol; 2013 Aug; 24(8):1209-17. PubMed ID: 23885916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors.
    Perry LJ; Stuart K; Stokes KR; Clouse ME
    Surgery; 1994 Dec; 116(6):1111-6; discussion 1116-7. PubMed ID: 7985095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study.
    Maire F; Lombard-Bohas C; O'Toole D; Vullierme MP; Rebours V; Couvelard A; Pelletier AL; Zappa M; Pilleul F; Hentic O; Hammel P; Ruszniewski P
    Neuroendocrinology; 2012; 96(4):294-300. PubMed ID: 22507901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
    Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF
    Cancer; 2018 May; 124(9):1992-2000. PubMed ID: 29451701
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes.
    Zener R; Yoon H; Ziv E; Covey A; Brown KT; Sofocleous CT; Thornton RH; Boas FE
    Cardiovasc Intervent Radiol; 2019 Apr; 42(4):569-576. PubMed ID: 30627774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
    Strosberg JR; Choi J; Cantor AB; Kvols LK
    Cancer Control; 2006 Jan; 13(1):72-8. PubMed ID: 16508629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial.
    He MK; Zou RH; Wei W; Shen JX; Zhao M; Zhang YF; Lin XJ; Zhang YJ; Guo RP; Shi M
    J Vasc Interv Radiol; 2018 Aug; 29(8):1068-1077.e2. PubMed ID: 30042075
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of raltitrexed-based transarterial chemoembolization for colorectal cancer liver metastases.
    Shao G; Liu R; Ding W; Lu L; Li W; Cao H; Liu R; Li C; Xiang H; Yang Z; Yang J; Song J; Wang J
    Anticancer Drugs; 2018 Nov; 29(10):1021-1025. PubMed ID: 30134285
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival.
    Mouli SK; Hickey R; Thornburg B; Sato KT; Desai K; Gabr A; Kallini JR; Niemeri H; Kircher S; Mulcahy MF; Benson Iii AB; Gupta R; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2016 Sep; 27(9):1279-1287. PubMed ID: 27062355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of doxorubicin loading on response and toxicity with drug-eluting embolization in resectable hepatoma: a dose escalation study.
    Klass D; Owen D; Buczkowski A; Chung SW; Scudamore CH; Weiss AA; Yoshida EM; Ford JA; Ho S; Liu DM
    Anticancer Res; 2014 Jul; 34(7):3597-606. PubMed ID: 24982375
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response.
    Suk Oh J; Jong Chun H; Gil Choi B; Giu Lee H
    J Vasc Interv Radiol; 2013 Apr; 24(4):483-9. PubMed ID: 23452553
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver.
    Salman HS; Cynamon J; Jagust M; Bakal C; Rozenblit A; Kaleya R; Negassa A; Wadler S
    Clin Colorectal Cancer; 2002 Nov; 2(3):173-9. PubMed ID: 12482334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.